Roche’s risdiplam shows significant improvement in survival and motor milestones in infants with Type 1 spinal muscular atrophy (SMA)

by NASDAQ Market News April 28, 2020

NASDAQ Market News
Click here to email author

New 6-year data for Roche’s OCREVUS (ocrelizumab) show earlier treatment initiation nearly halves risk of needing walking aid in relapsing multiple sclerosis

Cromos Pharma Supports R-Pharm in Initiation of a Global Program to Test Two of its Leading Candidates in Patients with Severe COVID-19 Infection. First Patients Have Been Recruited

Ads